AtaiBeckley (NASDAQ:ATAI) is a clinical-stage company that develops psychedelic drugs for mental health conditions. The company is now being acquired by the pharmaceutical giant Eli Lilly (NYSE: LLY). This strategic move is part of Eli Lilly's focus on new treatments for depression that aim to address the underlying causes of the illness.
On July 16, 2026, the investment firm Jefferies (NYSE: JEF) downgrades its rating on AtaiBeckley to Hold from a previous Buy rating. The firm also sets a new price target of $7.50 for the stock. A price target represents an analyst's projection of a stock's future price.
This new rating comes as AtaiBeckley's stock price closes at $7.15, which is 4.90% below the new price target. The stock's price surged by 33.40% today due to the acquisition news. The deal from Eli Lilly offers shareholders $6.75 in cash for each share.
The acquisition terms also include a Contingent Value Right (CVR) that could pay an additional $2.50 per share. A CVR is a potential future payment that shareholders receive only if the company achieves specific goals, such as regulatory approval for its new drugs.
The total value of the deal is up to $3.8 billion. However, as highlighted by PR Newswire, a law firm is investigating whether the deal provides fair value to shareholders. This uncertainty around the final payout may contribute to Jefferies' more cautious Hold rating.
